KR102537985B1 - Gpr120 조정제로서 유용한 단환형 화합물 - Google Patents
Gpr120 조정제로서 유용한 단환형 화합물 Download PDFInfo
- Publication number
- KR102537985B1 KR102537985B1 KR1020197010269A KR20197010269A KR102537985B1 KR 102537985 B1 KR102537985 B1 KR 102537985B1 KR 1020197010269 A KR1020197010269 A KR 1020197010269A KR 20197010269 A KR20197010269 A KR 20197010269A KR 102537985 B1 KR102537985 B1 KR 102537985B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- lcms
- esi
- nmr
- synthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393616P | 2016-09-12 | 2016-09-12 | |
| US62/393,616 | 2016-09-12 | ||
| PCT/US2017/050956 WO2018049324A1 (en) | 2016-09-12 | 2017-09-11 | Monocyclic compounds useful as gpr120 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190067174A KR20190067174A (ko) | 2019-06-14 |
| KR102537985B1 true KR102537985B1 (ko) | 2023-05-30 |
Family
ID=61562455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197010269A Active KR102537985B1 (ko) | 2016-09-12 | 2017-09-11 | Gpr120 조정제로서 유용한 단환형 화합물 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10800773B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3509587B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7086942B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102537985B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110225752B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018049324A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018049328A1 (en) * | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Bicyclic compounds useful as gpr120 modulators |
| KR102537985B1 (ko) | 2016-09-12 | 2023-05-30 | 인테그랄 헬스 인코퍼레이티드 | Gpr120 조정제로서 유용한 단환형 화합물 |
| US20210236443A1 (en) * | 2018-04-20 | 2021-08-05 | Krish Biotech Research Private Limited | Method of treatment of non-alcoholic steatohepatitis, nash |
| US11142525B2 (en) * | 2018-11-15 | 2021-10-12 | Pfizer Inc. | Azalactam compounds as HPK1 inhibitors |
| EP4143186A1 (en) | 2020-05-01 | 2023-03-08 | Pfizer Inc. | Azalactam compounds as hpk1 inhibitors |
| AU2021267930A1 (en) * | 2020-05-08 | 2022-12-22 | Georgiamune, Inc. | Akt3 modulators |
| CN114671827B (zh) * | 2020-12-24 | 2024-09-20 | 杭州百新生物医药科技有限公司 | 邻苯甲酰磺酰亚胺类衍生物及其应用 |
| KR102605163B1 (ko) * | 2021-06-01 | 2023-11-23 | 연세대학교 산학협력단 | 뇌암의 예방 또는 치료용 조성물 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010104195A1 (en) * | 2009-03-11 | 2010-09-16 | Banyu Pharmaceutical Co.,Ltd. | Novel isoindolin-1-one derivative |
| JP2016141618A (ja) * | 2015-01-29 | 2016-08-08 | 国立大学法人金沢大学 | 脱水縮合剤 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2735225A (en) * | 1956-02-21 | Table ix p petri dish tests with x-phthalimido- | ||
| DE2253251A1 (de) | 1972-10-30 | 1974-05-09 | Thomae Gmbh Dr K | Neue phthalimido-sulfonylharnstoffe |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US4165435A (en) * | 1976-06-25 | 1979-08-21 | Ciba-Geigy Corporation | Fire retardant s-triazine derivatives |
| DE3474547D1 (en) | 1983-12-02 | 1988-11-17 | Shell Int Research | Diphenyl ether herbicides |
| FR2659327A1 (fr) * | 1990-03-08 | 1991-09-13 | Centre Nat Rech Scient | Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases. |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5350761A (en) | 1991-07-30 | 1994-09-27 | Ciba-Geigy Corporation | Indolyl substituted hydroxylamine derivatives |
| ATE162525T1 (de) | 1991-07-30 | 1998-02-15 | Ciba Geigy Ag | Heteroaryl substituierte hydroxylaminderivate als lipoxygenase-inhibitoren |
| TW219935B (cg-RX-API-DMAC7.html) | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| NZ326874A (en) * | 1996-03-29 | 2000-01-28 | Pfizer | 6-phenylpyridyl-2-amine derivatives |
| US6716836B2 (en) | 2001-03-22 | 2004-04-06 | Boehringer Ingelheim (Canada) Ltd. | Non-nucleoside reverse transcriptase inhibitors |
| GB0124627D0 (en) | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| US8008525B2 (en) | 2003-11-26 | 2011-08-30 | Takeda Pharmaceutical Company Limited | Receptor function regulating agent |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| JP5405120B2 (ja) | 2006-12-01 | 2014-02-05 | Ｍｓｄ株式会社 | 新規フェニル−イソキサゾール−３−オール誘導体 |
| JP5421783B2 (ja) | 2006-12-27 | 2014-02-19 | サノフイ | Ｒｈｏキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体 |
| KR20090113901A (ko) | 2007-02-22 | 2009-11-02 | 아이알엠 엘엘씨 | Ｇ 단백질-커플링된 수용체를 조절하기 위한 화합물 및 방법 |
| KR20090113382A (ko) * | 2007-02-22 | 2009-10-30 | 아이알엠 엘엘씨 | Ｇ 단백질-커플링된 수용체의 조절제로서의 티아졸 유도체 |
| EP2151236A4 (en) | 2007-04-26 | 2013-01-16 | Japan Science & Tech Agency | G-PROTEIN-CONJUGATED RECEPTOR AGONIST |
| US8569378B2 (en) | 2007-07-20 | 2013-10-29 | Toshiyuki Sakai | p27 protein inducer |
| CA2725316A1 (en) | 2008-06-02 | 2009-12-10 | Banyu Pharmaceutical Co., Ltd. | Novel isoxazole derivative |
| EA022417B1 (ru) | 2008-10-21 | 2015-12-30 | Саймабэй Терапевтикс, Инк. | Арильные агонисты рецептора gpr120 и их применение |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| ES2526124T3 (es) | 2010-06-16 | 2015-01-07 | Cymabay Therapeutics, Inc. | Agonistas del receptor GPR120 y sus usos |
| JP2014520879A (ja) | 2011-07-15 | 2014-08-25 | ファイザー・インク | Ｇｐｒ１１９調節因子 |
| MX350717B (es) * | 2011-11-30 | 2017-09-14 | Hoffmann La Roche | Nuevos derivados biciclicos de dihidroisoquinolin-1-ona. |
| WO2013139341A1 (en) | 2012-03-20 | 2013-09-26 | Syddansk Universitet | Gpr120 receptor modulators |
| CN105073111A (zh) * | 2012-10-11 | 2015-11-18 | 默沙东公司 | 用作gpr120激动剂的取代的螺哌啶基化合物 |
| KR101942752B1 (ko) | 2012-11-05 | 2019-01-28 | 주식회사 엘지화학 | Ｇｐｒ120 효능제로서의 티오아릴 유도체 |
| EP2925746A1 (en) | 2012-12-03 | 2015-10-07 | F. Hoffmann-La Roche AG | Substituted triazole and imidazole compounds |
| EP2935257B1 (en) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
| BR112015021990A2 (pt) | 2013-03-14 | 2017-07-18 | Bristol Myers Squibb Co | moduladores de gpr120 de ácido biciclo [2.2.1] |
| WO2014159054A1 (en) | 2013-03-14 | 2014-10-02 | Janssen Pharmaceutica Nv | Gpr120 agonists for the treatment of type ii diabetes |
| JP6333355B2 (ja) | 2013-03-14 | 2018-05-30 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｇｐｒ１２０のアゴニストとして有用な二環式ピロール誘導体 |
| KR102422559B1 (ko) | 2013-03-14 | 2022-07-18 | 얀센 파마슈티카 엔.브이. | Gpr120의 작용제로서 유용한 벤조 융합된 헤테로사이클릭 유도체 |
| US8962660B2 (en) | 2013-03-14 | 2015-02-24 | Bristol-Myers Squibb Company | Oxabicyclo [2.2.2] acid GPR120 modulators |
| PT3013796T (pt) | 2013-06-27 | 2020-03-26 | Lg Chemical Ltd | Derivados biarílicos como agonistas de gpr120 |
| AR099937A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| DK3140296T3 (en) * | 2014-05-07 | 2018-07-23 | Bristol Myers Squibb Co | PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES |
| SG11201701578YA (en) | 2014-08-29 | 2017-03-30 | Chdi Foundation Inc | Probes for imaging huntingtin protein |
| WO2017068412A1 (en) | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| WO2018049328A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Bicyclic compounds useful as gpr120 modulators |
| KR102537985B1 (ko) | 2016-09-12 | 2023-05-30 | 인테그랄 헬스 인코퍼레이티드 | Gpr120 조정제로서 유용한 단환형 화합물 |
-
2017
- 2017-09-11 KR KR1020197010269A patent/KR102537985B1/ko active Active
- 2017-09-11 EP EP17849719.4A patent/EP3509587B1/en active Active
- 2017-09-11 US US16/331,916 patent/US10800773B2/en active Active
- 2017-09-11 WO PCT/US2017/050956 patent/WO2018049324A1/en not_active Ceased
- 2017-09-11 JP JP2019513935A patent/JP7086942B2/ja active Active
- 2017-09-11 CN CN201780068713.3A patent/CN110225752B/zh active Active
-
2020
- 2020-08-20 US US16/998,660 patent/US11548886B2/en active Active
-
2022
- 2022-10-03 US US17/959,064 patent/US12116362B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010104195A1 (en) * | 2009-03-11 | 2010-09-16 | Banyu Pharmaceutical Co.,Ltd. | Novel isoindolin-1-one derivative |
| JP2016141618A (ja) * | 2015-01-29 | 2016-08-08 | 国立大学法人金沢大学 | 脱水縮合剤 |
Non-Patent Citations (3)
| Title |
|---|
| Archiv de Pharmazie, 2016.03, 제349권, 페이지 175-185* |
| Asian Journal of Chemistry, 1991, 제3권, 페이지 30-37* |
| Journal of Medicinal Chemistry, 2016.06.17, 제59권, 페이지 6101-6120* |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190202821A1 (en) | 2019-07-04 |
| EP3509587A1 (en) | 2019-07-17 |
| US10800773B2 (en) | 2020-10-13 |
| US20210101896A1 (en) | 2021-04-08 |
| CA3041033A1 (en) | 2018-03-15 |
| KR20190067174A (ko) | 2019-06-14 |
| WO2018049324A1 (en) | 2018-03-15 |
| CN110225752A (zh) | 2019-09-10 |
| CN110225752B (zh) | 2023-05-05 |
| JP2019530674A (ja) | 2019-10-24 |
| US11548886B2 (en) | 2023-01-10 |
| US20230183231A1 (en) | 2023-06-15 |
| EP3509587C0 (en) | 2023-12-06 |
| EP3509587B1 (en) | 2023-12-06 |
| JP7086942B2 (ja) | 2022-06-20 |
| US12116362B2 (en) | 2024-10-15 |
| EP3509587A4 (en) | 2020-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12116362B2 (en) | Monocyclic compounds useful as GPR120 modulators | |
| KR102539877B1 (ko) | Gpr120 조정제로서 유용한 이환형 화합물 | |
| US11649224B2 (en) | IRE1 small molecule inhibitors | |
| DE60028354T2 (de) | Chemokine rezeptor bindende heterozyklische verbindungen | |
| US10745379B2 (en) | IRE1 small molecule inhibitors | |
| US10369146B2 (en) | Phenyl linked quinolinyl modulators of RORγt | |
| US20210214337A1 (en) | Substituted alkoxypyridinyl indolsulfonamides | |
| CN1411456A (zh) | 结合趋化因子受体的杂环化合物 | |
| US20250179017A1 (en) | Carboxamide compounds as pge2 receptor antagonists | |
| KR20230061482A (ko) | 인터페론 유전자 자극제 (stimulator of interferon genes)(STING) 의 작용제들 | |
| KR20160068948A (ko) | RORyt의 이차 알코올 퀴놀리닐 조절제 | |
| CA3041038C (en) | Bicyclic compounds useful as gpr120 modulators | |
| HK40005332A (en) | Monocyclic compounds useful as gpr120 modulators | |
| HK40005332B (en) | Monocyclic compounds useful as gpr120 modulators | |
| HK40005335A (en) | Bicyclic compounds useful as gpr120 modulators | |
| HK40005335B (en) | Bicyclic compounds useful as gpr120 modulators | |
| RU2804638C2 (ru) | Пиридинаминпиридоны и пиримидинаминпиридоны |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190410 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200907 Comment text: Request for Examination of Application |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20200923 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220622 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20230119 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20220622 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20230119 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20220916 Comment text: Amendment to Specification, etc. |
|
| PX0701 | Decision of registration after re-examination |
Patent event date: 20230503 Comment text: Decision to Grant Registration Patent event code: PX07013S01D Patent event date: 20230411 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20230119 Comment text: Decision to Refuse Application Patent event code: PX07011S01I Patent event date: 20220916 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230524 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20230525 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |